Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-08-14
2010-06-22
Reddig, Peter J (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S387700, C530S388100, C530S388150, C530S388800, C530S809000
Reexamination Certificate
active
07741444
ABSTRACT:
The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms.
REFERENCES:
patent: 5001225 (1991-03-01), Taylor
patent: 5610280 (1997-03-01), Brandt et al.
patent: 5639863 (1997-06-01), Dan
patent: 5763224 (1998-06-01), Caras et al.
patent: 6677442 (2004-01-01), Wang et al.
patent: 6995240 (2006-02-01), Panayi et al.
patent: 7049132 (2006-05-01), Lee
patent: 2003/0105000 (2003-06-01), Pero et al.
patent: 2004/0180002 (2004-09-01), Young et al.
patent: 2004/0197328 (2004-10-01), Young et al.
patent: 2004/0258693 (2004-12-01), Young et al.
patent: 2005/0123571 (2005-06-01), Rossini et al.
patent: 41 07 154 (1992-04-01), None
patent: 692 12 671 (1997-03-01), None
patent: 692 29 110 (1999-11-01), None
patent: 695 27 975 (2003-03-01), None
patent: 0 502 812 (1996-08-01), None
patent: 0 502 812 (1996-08-01), None
patent: 1 106 183 (2001-06-01), None
patent: 1 106 183 (2001-06-01), None
patent: 1 141 019 (2004-04-01), None
patent: 92/16624 (1992-10-01), None
patent: 96/16990 (1996-06-01), None
patent: 97/02479 (1997-01-01), None
patent: 97/13844 (1997-04-01), None
patent: 99/28461 (1999-06-01), None
patent: 99/53051 (1999-10-01), None
patent: 99/65935 (1999-12-01), None
patent: 00/37489 (2000-06-01), None
patent: 00/37489 (2000-06-01), None
patent: 01/62932 (2001-08-01), None
patent: 01/83560 (2001-11-01), None
patent: WO/2003/048321 (2001-12-01), None
patent: 02/12502 (2002-02-01), None
patent: 02/084277 (2002-10-01), None
patent: 03/011907 (2003-02-01), None
patent: 03/076472 (2003-09-01), None
patent: 03/076472 (2003-09-01), None
patent: 2004/005351 (2004-01-01), None
patent: 2004/020999 (2004-03-01), None
patent: 2004/081027 (2004-09-01), None
patent: 2004/081027 (2004-09-01), None
patent: 2005/001052 (2005-01-01), None
patent: 2005/045428 (2005-05-01), None
patent: 2005/047332 (2005-05-01), None
patent: 2005/065418 (2005-07-01), None
patent: 2005/092922 (2005-10-01), None
patent: 2005/092922 (2005-10-01), None
patent: 2005/094159 (2005-10-01), None
Overholser et al. (Cancer 2000 89 (1): 74-82).
Goldstein et al. (Clin. Cancer Research 1995 1: 1311-1318)
Berger, C.L., et al., A Lymphocyte Cell Surface Heat Shock Protein Homologous to the Endoplasmic Reticulum Chaperone, Immunoglobulin Heavy Chain Binding Protein BIP, Int. J. Cancer, 71:1077-1085 (1997).
Bjorge et al., Complement-Regulatory Proteins in Ovarian Malignancies, Int. J. Cancer, 70:14-25 (1997).
Brandlein et al., “Natural IgM Antibodies and Immunosurveillance Mechanisms Against Epithelial Cancer Cells in Humans,” Cancer Research, 63: 7995-8005, Nov. 15, 2003.
Brändlein et al., Characterization of Five New Fully Human Monoclonal IgM Antibodies Isolated from Carcinoma Patients, Proceedings of the Annual Meeting of the American Association for Cancer Research 43:970, Mar. 2002 (Abstract).
Brändlein et al., Human Monoclonal IgM Antibodies with Apoptotic Activity isolated from Cancer Patients, Human Antibodies 11:107-119, 2002.
Brändlein, S., et al., CFR-1 Receptor as Target for Tumor-specific Apoptosis Induced by the Natural Human Monoclonal Antibody PAM-1, Oncology Reports, 11:777-784 (2004).
Brändlein, S., et al., Cysteine-rich Fibroblast Growth Factor Receptor 1, a New Marker for Precancerous Epithelial Lesions Defined by the Human Monoclonal Antibody PAM-1, Cancer Research, 63:2052-2061 (2003).
Brändlein, S., et al., PAM-1, a Natural Human IgM Antibody as New Tool for Detection of Breast and Prostate Precursors, Human Antibodies, 13:97-104 (2004).
Chen, G., et al., Protein Profiles Associated With Survival in Lung Adenocarcinoma, www.pnas.org/cgi/doi/10.1073/pnas.2233850100 pp. 1-6 (2003).
Database entry AAB02178 dated Jun. 11, 1996.
Faller et al., HAB-1, a New Heteromyeloma for Continuous Production of Human Monoclonal Antibodies, Br. J. Cancer 62:595-598 (1990).
Gibbs et al., The function of the Human Homolog ofS. CerevisiaeREV1 is required for mutagenesis induced by UV light, PNAS 97:8, 4186-4191, Apr. 11, 2000.
Gonatas et al., MG-160, A Membrane Sialoglycoprotein of the Medial Cisternae of the Rat Golgi Apparatus, Binds Basic Fibroblast Growth Factor and Exhibits a High level of Sequence Identity to a Chicken Fibroblast Growth Factor Receptor, J. Cell Science 108:457-467, 1995.
Grossman, H.B., Natural Antibody to a Human Bladder Carcinoma Cell Line, Cancer Immunol. Immunother. 13:89-92 (1982).
Hensel et al., A New Variant of Cystein-Rich FGF Receptor (CFR-1) Specifically Expressed on Tumor Cells, Proceedings of the American Association for Cancer Research 41:698 (abstract 4438), Mar. 2000.
Hensel et al., A Novel Proliferation-associated Variant of CFR-1 Defined by a Human Monoclonal Antibody, Laboratory Investigation 81:1097-1108, 2001.
Hensel et al., Characterization of Glycosylphosphatidylinositol-linked Molecule CD55/Decay-accelerating Factor as the Receptor for Antibody SC-1-induced Apoptosis, Cancer Research 59:5299-5306, 1999.
Hensel et al., Mitogenic Autoantibodies in Helicobacter pylori-Associated Stomach Cancerogenesis, International Journal of Cancer 81:229-235, 1999.
Hensel, F., et al., “Regulation of the new coexpressed CD55 (decay-accelerating factor) receptor on stomach carcinoma cells involved in antibody SC-1-induced apoptosis”, Laboratory Investigation, 81(11):1553-1563 (2001).
Huang et al., Sulindac Sulfide-induced Apoptosis Involves Death Receptor 5 and the Caspase 8-dependent Pathway in Human Colon and Prostate Cancer Cells, Cancer Research 61:6918-6924 (2001).
Jamora, C., et al., Inhibition of Tumor Progression by Suppression of Stress Protein GRP78/BiP Induction in Fibrosarcoma B/C1OME, Proc. Natl. Acad. Sci. USA, 93:7690-7694 (1996).
Jansson, et al., The Human Repertoire of Antibody Specificities Against Thomsen-Friedenreich and TN-carcinoma-associated antigens as defined by Monoclonal Antibodies, Cancer Immunology 34:294-298, 1992.
Kamitani, H., et al., Expression of 15-Lipoxygenase by Human Colerectal Carcinoma Caco-2 Cells During Apoptosis and Cell Differentiation, The Journal of Biological Chemistry, 273(34):21569-21577 (1998).
Lee, A.S., Mammalian Stress Response: Induction of the Glucose-Regulated Protein Family, Current Opinion in Cell Biology, 4:267-273 (1992).
Mammalian Gene Collection (MGC) Program Team, “Generation and Initial Analysis of more than 15,000 Full-Length Human and Mouse cDNA Sequences” PNAS USA 99:16,899-16,903 (2002).
Mintz, P.J., et al., Fingerprinting the Circulating Repertoire of Antibodies from Cancer Patients, Nature Biotechnology, 21:57-63 (2003).
Mourelatos et al., Cloning and Sequence Analysis of the Human MG160, a Fibroblast Growth Factor and E-Selectin Binding Membrane Sialoglycoprotein of the Golgi Apparatus, DNA Cell Biol. 12:1121-1128 (1996).
Pfaff, M., et al., Human Monoclonal Antibody Against a Tissue Polypeptide Antigen-related Protein from a Patient with a Signet-Ring Cell Carcinoma of the Stomach, Cancer Research, 50:5192-5198 (1990).
Sato, K., et al., Immunotherapy Using Heat-Shock Protein Preparations of Leukemia Cells After Syngenic Bone Marrow Transplantation in Mice, Blood, 98(6):1852-1857 (2001).
Sugawara, S., et al., Suppression of Stress Protein GRP78 Induction in Tumor B/C1OME Eliminates Resistance to Cell Mediated Cytotoxicity, Cancer Research, 53:6001-6005 (1993).
Timmermann W., et al., Immuntherapie: ein Antikörper gegen Magenkrebs Blick 1/1999, Artikel 6, internet page http://www.uni-wuerzburg.de/blick1999-1/991do6-t.html.
Vollmers et al., “Apoptosis of Stomach Carcinoma Cells Induced by a Human Monoclonal Antibody,” Cancer 76:550-558 (1995).
Vollmers et al., “Human Monoclonal Antibodies from Stomach Carcinoma Patients React withHelicobacter pyloriand Stimulate Stomach Cells in vitro,” Cancer 74:1525-1532, 1994.
Vollmers et al., “SC-1, a Functional Human Monoclonal Antibody against Autologous Stomach Carcinoma Cells,” Cancer Res. 49:2471-2476, 1989.
Vollmers et al., Adjuvant Therapy for Gastric Adenocarcinoma with the Apoptosis-Inducing Human Monoclonal Antibody SC-1
Mueller-Hermelink Hans-Konrad
Vollmers Heinz Peter
Patrys Limited
Pillsburg Winthrop Shaw Pittman LLP
Reddig Peter J
LandOfFree
Neoplasm specific antibodies and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neoplasm specific antibodies and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neoplasm specific antibodies and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4179539